Global Antihypertensive Drugs
Global Antihypertensive Drugs

Antihypertensive Drugs Comprehensive Study by Disease Type (Primary Hypertension, Secondary Hypertension), End-users (Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others), Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others) Players and Region - Global Market Outlook to 2026

Antihypertensive Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 205 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antihypertensive Drugs Market?

Antihypertensive drugs are a class of drugs that are used to treat hypertension which prevents complications of high blood pressure, such as stroke and myocardial infarction. These drugs are frequently used by patients and may influence the conduct of anesthesia. The most important and widely used medications are thiazide diuretics, calcium channel blockers, ACE inhibitors, angiotensin II receptor antagonists (ARBs), and beta-blockers.

The market study is being classified and major geographies with country level break-up.

Novartis International AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson (United States), Sanofi S.A (France), Lupin Limited (India), Ranbaxy Laboratories (India), Merck & Co. (United States), AstraZeneca plc (United Kingdom), Daiichi Sankyo Company (Japan) and Takeda Pharmaceutical Company (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Actelion (Switzerland) and United Therapeutics Corporation (United States).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antihypertensive Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Antihypertensive Drugs market by Type, Application and Region.

On the basis of geography, the market of Antihypertensive Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Hypertension Worldwide
  • Rise in the Number of Hypertension Cases Spreading Awareness
  • Increased Number of Online Pharmacies

Market Trend
  • Increased Research and Development Activities
  • High Demand for Effective Treatments for Hypertension

Restraints
  • Side Effects of the Antihypertensive Drugs
  • Low Awareness in Developing Countries

Opportunities
  • Increasing Preference for Combination Therapy
  • Growth in the Healthcare Industry Worldwide
  • Robust Increase in the Distribution Channels

Challenges
  • Stringent Government Rules and Regulations for Drug Approvals


Market Leaders and some development strategies
In August 2020, Johnson & Johnson has announced that it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all-cash transaction.



Key Target Audience
Antihypertensive Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Disease Type
  • Primary Hypertension
  • Secondary Hypertension

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Retail Pharmacy
  • Hospital Pharmacy
  • E-commerce Websites & Online Drug Stores
  • Others

By Therapeutic Class
  • Calcium Channel Blockers
  • Beta-adrenergic Blockers
  • Renin Inhibitors
  • ACE Inhibitors
  • Vasodilators
  • Diuretics
  • ARBs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Hypertension Worldwide
      • 3.2.2. Rise in the Number of Hypertension Cases Spreading Awareness
      • 3.2.3. Increased Number of Online Pharmacies
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations for Drug Approvals
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. High Demand for Effective Treatments for Hypertension
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antihypertensive Drugs, by Disease Type, End-users, Distribution Channel, Therapeutic Class and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antihypertensive Drugs (Value)
      • 5.2.1. Global Antihypertensive Drugs by: Disease Type (Value)
        • 5.2.1.1. Primary Hypertension
        • 5.2.1.2. Secondary Hypertension
      • 5.2.2. Global Antihypertensive Drugs by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Antihypertensive Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacy
        • 5.2.3.2. Hospital Pharmacy
        • 5.2.3.3. E-commerce Websites & Online Drug Stores
        • 5.2.3.4. Others
      • 5.2.4. Global Antihypertensive Drugs by: Therapeutic Class (Value)
        • 5.2.4.1. Calcium Channel Blockers
        • 5.2.4.2. Beta-adrenergic Blockers
        • 5.2.4.3. Renin Inhibitors
        • 5.2.4.4. ACE Inhibitors
        • 5.2.4.5. Vasodilators
        • 5.2.4.6. Diuretics
        • 5.2.4.7. ARBs
        • 5.2.4.8. Others
      • 5.2.5. Global Antihypertensive Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antihypertensive Drugs (Volume)
      • 5.3.1. Global Antihypertensive Drugs by: Disease Type (Volume)
        • 5.3.1.1. Primary Hypertension
        • 5.3.1.2. Secondary Hypertension
      • 5.3.2. Global Antihypertensive Drugs by: End-users (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Antihypertensive Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Retail Pharmacy
        • 5.3.3.2. Hospital Pharmacy
        • 5.3.3.3. E-commerce Websites & Online Drug Stores
        • 5.3.3.4. Others
      • 5.3.4. Global Antihypertensive Drugs by: Therapeutic Class (Volume)
        • 5.3.4.1. Calcium Channel Blockers
        • 5.3.4.2. Beta-adrenergic Blockers
        • 5.3.4.3. Renin Inhibitors
        • 5.3.4.4. ACE Inhibitors
        • 5.3.4.5. Vasodilators
        • 5.3.4.6. Diuretics
        • 5.3.4.7. ARBs
        • 5.3.4.8. Others
      • 5.3.5. Global Antihypertensive Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Antihypertensive Drugs (Price)
  • 6. Antihypertensive Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi S.A (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lupin Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ranbaxy Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Daiichi Sankyo Company (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Takeda Pharmaceutical Company (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antihypertensive Drugs Sale, by Disease Type, End-users, Distribution Channel, Therapeutic Class and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antihypertensive Drugs (Value)
      • 7.2.1. Global Antihypertensive Drugs by: Disease Type (Value)
        • 7.2.1.1. Primary Hypertension
        • 7.2.1.2. Secondary Hypertension
      • 7.2.2. Global Antihypertensive Drugs by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Antihypertensive Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacy
        • 7.2.3.2. Hospital Pharmacy
        • 7.2.3.3. E-commerce Websites & Online Drug Stores
        • 7.2.3.4. Others
      • 7.2.4. Global Antihypertensive Drugs by: Therapeutic Class (Value)
        • 7.2.4.1. Calcium Channel Blockers
        • 7.2.4.2. Beta-adrenergic Blockers
        • 7.2.4.3. Renin Inhibitors
        • 7.2.4.4. ACE Inhibitors
        • 7.2.4.5. Vasodilators
        • 7.2.4.6. Diuretics
        • 7.2.4.7. ARBs
        • 7.2.4.8. Others
      • 7.2.5. Global Antihypertensive Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antihypertensive Drugs (Volume)
      • 7.3.1. Global Antihypertensive Drugs by: Disease Type (Volume)
        • 7.3.1.1. Primary Hypertension
        • 7.3.1.2. Secondary Hypertension
      • 7.3.2. Global Antihypertensive Drugs by: End-users (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Antihypertensive Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Retail Pharmacy
        • 7.3.3.2. Hospital Pharmacy
        • 7.3.3.3. E-commerce Websites & Online Drug Stores
        • 7.3.3.4. Others
      • 7.3.4. Global Antihypertensive Drugs by: Therapeutic Class (Volume)
        • 7.3.4.1. Calcium Channel Blockers
        • 7.3.4.2. Beta-adrenergic Blockers
        • 7.3.4.3. Renin Inhibitors
        • 7.3.4.4. ACE Inhibitors
        • 7.3.4.5. Vasodilators
        • 7.3.4.6. Diuretics
        • 7.3.4.7. ARBs
        • 7.3.4.8. Others
      • 7.3.5. Global Antihypertensive Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Antihypertensive Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antihypertensive Drugs: by Disease Type(USD Million)
  • Table 2. Antihypertensive Drugs Primary Hypertension , by Region USD Million (2015-2020)
  • Table 3. Antihypertensive Drugs Secondary Hypertension , by Region USD Million (2015-2020)
  • Table 4. Antihypertensive Drugs: by End-users(USD Million)
  • Table 5. Antihypertensive Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 6. Antihypertensive Drugs Clinics , by Region USD Million (2015-2020)
  • Table 7. Antihypertensive Drugs Others , by Region USD Million (2015-2020)
  • Table 8. Antihypertensive Drugs: by Distribution Channel(USD Million)
  • Table 9. Antihypertensive Drugs Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 10. Antihypertensive Drugs Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 11. Antihypertensive Drugs E-commerce Websites & Online Drug Stores , by Region USD Million (2015-2020)
  • Table 12. Antihypertensive Drugs Others , by Region USD Million (2015-2020)
  • Table 13. Antihypertensive Drugs: by Therapeutic Class(USD Million)
  • Table 14. Antihypertensive Drugs Calcium Channel Blockers , by Region USD Million (2015-2020)
  • Table 15. Antihypertensive Drugs Beta-adrenergic Blockers , by Region USD Million (2015-2020)
  • Table 16. Antihypertensive Drugs Renin Inhibitors , by Region USD Million (2015-2020)
  • Table 17. Antihypertensive Drugs ACE Inhibitors , by Region USD Million (2015-2020)
  • Table 18. Antihypertensive Drugs Vasodilators , by Region USD Million (2015-2020)
  • Table 19. Antihypertensive Drugs Diuretics , by Region USD Million (2015-2020)
  • Table 20. Antihypertensive Drugs ARBs , by Region USD Million (2015-2020)
  • Table 21. Antihypertensive Drugs Others , by Region USD Million (2015-2020)
  • Table 22. South America Antihypertensive Drugs, by Country USD Million (2015-2020)
  • Table 23. South America Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 24. South America Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 25. South America Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 26. South America Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 27. Brazil Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 28. Brazil Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 29. Brazil Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 30. Brazil Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 31. Argentina Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 32. Argentina Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 33. Argentina Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 34. Argentina Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 35. Rest of South America Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 36. Rest of South America Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 37. Rest of South America Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. Rest of South America Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 39. Asia Pacific Antihypertensive Drugs, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 41. Asia Pacific Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 42. Asia Pacific Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 43. Asia Pacific Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 44. China Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 45. China Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 46. China Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. China Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 48. Japan Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 49. Japan Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 50. Japan Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Japan Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 52. India Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 53. India Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 54. India Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 55. India Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 56. South Korea Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 57. South Korea Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 58. South Korea Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 59. South Korea Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 60. Taiwan Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 61. Taiwan Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 62. Taiwan Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. Taiwan Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 64. Australia Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 65. Australia Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 66. Australia Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 67. Australia Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 72. Europe Antihypertensive Drugs, by Country USD Million (2015-2020)
  • Table 73. Europe Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 74. Europe Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 75. Europe Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Europe Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 77. Germany Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 78. Germany Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 79. Germany Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 80. Germany Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 81. France Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 82. France Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 83. France Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 84. France Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 85. Italy Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 86. Italy Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 87. Italy Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 88. Italy Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 89. United Kingdom Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 90. United Kingdom Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 91. United Kingdom Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. United Kingdom Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 93. Netherlands Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 94. Netherlands Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 95. Netherlands Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 96. Netherlands Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 97. Rest of Europe Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 98. Rest of Europe Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 99. Rest of Europe Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 100. Rest of Europe Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 101. MEA Antihypertensive Drugs, by Country USD Million (2015-2020)
  • Table 102. MEA Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 103. MEA Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 104. MEA Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 105. MEA Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 106. Middle East Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 107. Middle East Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 108. Middle East Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 109. Middle East Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 110. Africa Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 111. Africa Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 112. Africa Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 113. Africa Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 114. North America Antihypertensive Drugs, by Country USD Million (2015-2020)
  • Table 115. North America Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 116. North America Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 117. North America Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 118. North America Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 119. United States Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 120. United States Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 121. United States Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 122. United States Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 123. Canada Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 124. Canada Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 125. Canada Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 126. Canada Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 127. Mexico Antihypertensive Drugs, by Disease Type USD Million (2015-2020)
  • Table 128. Mexico Antihypertensive Drugs, by End-users USD Million (2015-2020)
  • Table 129. Mexico Antihypertensive Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 130. Mexico Antihypertensive Drugs, by Therapeutic Class USD Million (2015-2020)
  • Table 131. Antihypertensive Drugs Sales: by Disease Type(K Units)
  • Table 132. Antihypertensive Drugs Sales Primary Hypertension , by Region K Units (2015-2020)
  • Table 133. Antihypertensive Drugs Sales Secondary Hypertension , by Region K Units (2015-2020)
  • Table 134. Antihypertensive Drugs Sales: by End-users(K Units)
  • Table 135. Antihypertensive Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 136. Antihypertensive Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 137. Antihypertensive Drugs Sales Others , by Region K Units (2015-2020)
  • Table 138. Antihypertensive Drugs Sales: by Distribution Channel(K Units)
  • Table 139. Antihypertensive Drugs Sales Retail Pharmacy , by Region K Units (2015-2020)
  • Table 140. Antihypertensive Drugs Sales Hospital Pharmacy , by Region K Units (2015-2020)
  • Table 141. Antihypertensive Drugs Sales E-commerce Websites & Online Drug Stores , by Region K Units (2015-2020)
  • Table 142. Antihypertensive Drugs Sales Others , by Region K Units (2015-2020)
  • Table 143. Antihypertensive Drugs Sales: by Therapeutic Class(K Units)
  • Table 144. Antihypertensive Drugs Sales Calcium Channel Blockers , by Region K Units (2015-2020)
  • Table 145. Antihypertensive Drugs Sales Beta-adrenergic Blockers , by Region K Units (2015-2020)
  • Table 146. Antihypertensive Drugs Sales Renin Inhibitors , by Region K Units (2015-2020)
  • Table 147. Antihypertensive Drugs Sales ACE Inhibitors , by Region K Units (2015-2020)
  • Table 148. Antihypertensive Drugs Sales Vasodilators , by Region K Units (2015-2020)
  • Table 149. Antihypertensive Drugs Sales Diuretics , by Region K Units (2015-2020)
  • Table 150. Antihypertensive Drugs Sales ARBs , by Region K Units (2015-2020)
  • Table 151. Antihypertensive Drugs Sales Others , by Region K Units (2015-2020)
  • Table 152. South America Antihypertensive Drugs Sales, by Country K Units (2015-2020)
  • Table 153. South America Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 154. South America Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 155. South America Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 156. South America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 157. Brazil Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 158. Brazil Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 159. Brazil Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 160. Brazil Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 161. Argentina Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 162. Argentina Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 163. Argentina Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. Argentina Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 165. Rest of South America Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 166. Rest of South America Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 167. Rest of South America Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 168. Rest of South America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 169. Asia Pacific Antihypertensive Drugs Sales, by Country K Units (2015-2020)
  • Table 170. Asia Pacific Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 171. Asia Pacific Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 172. Asia Pacific Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. Asia Pacific Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 174. China Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 175. China Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 176. China Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. China Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 178. Japan Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 179. Japan Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 180. Japan Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 181. Japan Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 182. India Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 183. India Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 184. India Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 185. India Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 186. South Korea Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 187. South Korea Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 188. South Korea Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 189. South Korea Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 190. Taiwan Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 191. Taiwan Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 192. Taiwan Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Taiwan Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 194. Australia Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 195. Australia Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 196. Australia Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 197. Australia Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 198. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 199. Rest of Asia-Pacific Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 200. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 201. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 202. Europe Antihypertensive Drugs Sales, by Country K Units (2015-2020)
  • Table 203. Europe Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 204. Europe Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 205. Europe Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. Europe Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 207. Germany Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 208. Germany Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 209. Germany Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 210. Germany Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 211. France Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 212. France Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 213. France Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 214. France Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 215. Italy Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 216. Italy Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 217. Italy Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 218. Italy Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 219. United Kingdom Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 220. United Kingdom Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 221. United Kingdom Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 222. United Kingdom Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 223. Netherlands Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 224. Netherlands Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 225. Netherlands Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 226. Netherlands Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 227. Rest of Europe Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 228. Rest of Europe Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 229. Rest of Europe Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 230. Rest of Europe Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 231. MEA Antihypertensive Drugs Sales, by Country K Units (2015-2020)
  • Table 232. MEA Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 233. MEA Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 234. MEA Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 235. MEA Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 236. Middle East Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 237. Middle East Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 238. Middle East Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 239. Middle East Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 240. Africa Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 241. Africa Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 242. Africa Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 243. Africa Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 244. North America Antihypertensive Drugs Sales, by Country K Units (2015-2020)
  • Table 245. North America Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 246. North America Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 247. North America Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 248. North America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 249. United States Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 250. United States Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 251. United States Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 252. United States Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 253. Canada Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 254. Canada Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 255. Canada Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 256. Canada Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 257. Mexico Antihypertensive Drugs Sales, by Disease Type K Units (2015-2020)
  • Table 258. Mexico Antihypertensive Drugs Sales, by End-users K Units (2015-2020)
  • Table 259. Mexico Antihypertensive Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 260. Mexico Antihypertensive Drugs Sales, by Therapeutic Class K Units (2015-2020)
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Antihypertensive Drugs: by Disease Type(USD Million)
  • Table 272. Antihypertensive Drugs Primary Hypertension , by Region USD Million (2021-2026)
  • Table 273. Antihypertensive Drugs Secondary Hypertension , by Region USD Million (2021-2026)
  • Table 274. Antihypertensive Drugs: by End-users(USD Million)
  • Table 275. Antihypertensive Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 276. Antihypertensive Drugs Clinics , by Region USD Million (2021-2026)
  • Table 277. Antihypertensive Drugs Others , by Region USD Million (2021-2026)
  • Table 278. Antihypertensive Drugs: by Distribution Channel(USD Million)
  • Table 279. Antihypertensive Drugs Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 280. Antihypertensive Drugs Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 281. Antihypertensive Drugs E-commerce Websites & Online Drug Stores , by Region USD Million (2021-2026)
  • Table 282. Antihypertensive Drugs Others , by Region USD Million (2021-2026)
  • Table 283. Antihypertensive Drugs: by Therapeutic Class(USD Million)
  • Table 284. Antihypertensive Drugs Calcium Channel Blockers , by Region USD Million (2021-2026)
  • Table 285. Antihypertensive Drugs Beta-adrenergic Blockers , by Region USD Million (2021-2026)
  • Table 286. Antihypertensive Drugs Renin Inhibitors , by Region USD Million (2021-2026)
  • Table 287. Antihypertensive Drugs ACE Inhibitors , by Region USD Million (2021-2026)
  • Table 288. Antihypertensive Drugs Vasodilators , by Region USD Million (2021-2026)
  • Table 289. Antihypertensive Drugs Diuretics , by Region USD Million (2021-2026)
  • Table 290. Antihypertensive Drugs ARBs , by Region USD Million (2021-2026)
  • Table 291. Antihypertensive Drugs Others , by Region USD Million (2021-2026)
  • Table 292. South America Antihypertensive Drugs, by Country USD Million (2021-2026)
  • Table 293. South America Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 294. South America Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 295. South America Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 296. South America Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 297. Brazil Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 298. Brazil Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 299. Brazil Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 300. Brazil Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 301. Argentina Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 302. Argentina Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 303. Argentina Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 304. Argentina Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 305. Rest of South America Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 306. Rest of South America Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 307. Rest of South America Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 308. Rest of South America Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 309. Asia Pacific Antihypertensive Drugs, by Country USD Million (2021-2026)
  • Table 310. Asia Pacific Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 311. Asia Pacific Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 312. Asia Pacific Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 313. Asia Pacific Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 314. China Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 315. China Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 316. China Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 317. China Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 318. Japan Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 319. Japan Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 320. Japan Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 321. Japan Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 322. India Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 323. India Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 324. India Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 325. India Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 326. South Korea Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 327. South Korea Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 328. South Korea Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 329. South Korea Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 330. Taiwan Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 331. Taiwan Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 332. Taiwan Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 333. Taiwan Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 334. Australia Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 335. Australia Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 336. Australia Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 337. Australia Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 338. Rest of Asia-Pacific Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 339. Rest of Asia-Pacific Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 340. Rest of Asia-Pacific Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 341. Rest of Asia-Pacific Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 342. Europe Antihypertensive Drugs, by Country USD Million (2021-2026)
  • Table 343. Europe Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 344. Europe Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 345. Europe Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 346. Europe Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 347. Germany Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 348. Germany Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 349. Germany Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 350. Germany Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 351. France Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 352. France Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 353. France Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 354. France Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 355. Italy Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 356. Italy Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 357. Italy Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 358. Italy Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 359. United Kingdom Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 360. United Kingdom Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 361. United Kingdom Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 362. United Kingdom Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 363. Netherlands Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 364. Netherlands Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 365. Netherlands Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 366. Netherlands Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 367. Rest of Europe Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 368. Rest of Europe Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 369. Rest of Europe Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 370. Rest of Europe Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 371. MEA Antihypertensive Drugs, by Country USD Million (2021-2026)
  • Table 372. MEA Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 373. MEA Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 374. MEA Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 375. MEA Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 376. Middle East Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 377. Middle East Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 378. Middle East Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 379. Middle East Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 380. Africa Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 381. Africa Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 382. Africa Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 383. Africa Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 384. North America Antihypertensive Drugs, by Country USD Million (2021-2026)
  • Table 385. North America Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 386. North America Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 387. North America Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 388. North America Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 389. United States Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 390. United States Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 391. United States Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 392. United States Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 393. Canada Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 394. Canada Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 395. Canada Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 396. Canada Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 397. Mexico Antihypertensive Drugs, by Disease Type USD Million (2021-2026)
  • Table 398. Mexico Antihypertensive Drugs, by End-users USD Million (2021-2026)
  • Table 399. Mexico Antihypertensive Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 400. Mexico Antihypertensive Drugs, by Therapeutic Class USD Million (2021-2026)
  • Table 401. Antihypertensive Drugs Sales: by Disease Type(K Units)
  • Table 402. Antihypertensive Drugs Sales Primary Hypertension , by Region K Units (2021-2026)
  • Table 403. Antihypertensive Drugs Sales Secondary Hypertension , by Region K Units (2021-2026)
  • Table 404. Antihypertensive Drugs Sales: by End-users(K Units)
  • Table 405. Antihypertensive Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 406. Antihypertensive Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 407. Antihypertensive Drugs Sales Others , by Region K Units (2021-2026)
  • Table 408. Antihypertensive Drugs Sales: by Distribution Channel(K Units)
  • Table 409. Antihypertensive Drugs Sales Retail Pharmacy , by Region K Units (2021-2026)
  • Table 410. Antihypertensive Drugs Sales Hospital Pharmacy , by Region K Units (2021-2026)
  • Table 411. Antihypertensive Drugs Sales E-commerce Websites & Online Drug Stores , by Region K Units (2021-2026)
  • Table 412. Antihypertensive Drugs Sales Others , by Region K Units (2021-2026)
  • Table 413. Antihypertensive Drugs Sales: by Therapeutic Class(K Units)
  • Table 414. Antihypertensive Drugs Sales Calcium Channel Blockers , by Region K Units (2021-2026)
  • Table 415. Antihypertensive Drugs Sales Beta-adrenergic Blockers , by Region K Units (2021-2026)
  • Table 416. Antihypertensive Drugs Sales Renin Inhibitors , by Region K Units (2021-2026)
  • Table 417. Antihypertensive Drugs Sales ACE Inhibitors , by Region K Units (2021-2026)
  • Table 418. Antihypertensive Drugs Sales Vasodilators , by Region K Units (2021-2026)
  • Table 419. Antihypertensive Drugs Sales Diuretics , by Region K Units (2021-2026)
  • Table 420. Antihypertensive Drugs Sales ARBs , by Region K Units (2021-2026)
  • Table 421. Antihypertensive Drugs Sales Others , by Region K Units (2021-2026)
  • Table 422. South America Antihypertensive Drugs Sales, by Country K Units (2021-2026)
  • Table 423. South America Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 424. South America Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 425. South America Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 426. South America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 427. Brazil Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 428. Brazil Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 429. Brazil Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 430. Brazil Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 431. Argentina Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 432. Argentina Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 433. Argentina Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 434. Argentina Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 435. Rest of South America Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 436. Rest of South America Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 437. Rest of South America Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 438. Rest of South America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 439. Asia Pacific Antihypertensive Drugs Sales, by Country K Units (2021-2026)
  • Table 440. Asia Pacific Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 441. Asia Pacific Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 442. Asia Pacific Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 443. Asia Pacific Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 444. China Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 445. China Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 446. China Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 447. China Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 448. Japan Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 449. Japan Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 450. Japan Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 451. Japan Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 452. India Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 453. India Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 454. India Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 455. India Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 456. South Korea Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 457. South Korea Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 458. South Korea Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 459. South Korea Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 460. Taiwan Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 461. Taiwan Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 462. Taiwan Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 463. Taiwan Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 464. Australia Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 465. Australia Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 466. Australia Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 467. Australia Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 468. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 469. Rest of Asia-Pacific Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 470. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 471. Rest of Asia-Pacific Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 472. Europe Antihypertensive Drugs Sales, by Country K Units (2021-2026)
  • Table 473. Europe Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 474. Europe Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 475. Europe Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 476. Europe Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 477. Germany Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 478. Germany Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 479. Germany Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 480. Germany Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 481. France Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 482. France Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 483. France Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 484. France Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 485. Italy Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 486. Italy Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 487. Italy Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 488. Italy Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 489. United Kingdom Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 490. United Kingdom Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 491. United Kingdom Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 492. United Kingdom Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 493. Netherlands Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 494. Netherlands Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 495. Netherlands Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 496. Netherlands Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 497. Rest of Europe Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 498. Rest of Europe Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 499. Rest of Europe Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 500. Rest of Europe Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 501. MEA Antihypertensive Drugs Sales, by Country K Units (2021-2026)
  • Table 502. MEA Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 503. MEA Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 504. MEA Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 505. MEA Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 506. Middle East Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 507. Middle East Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 508. Middle East Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 509. Middle East Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 510. Africa Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 511. Africa Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 512. Africa Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 513. Africa Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 514. North America Antihypertensive Drugs Sales, by Country K Units (2021-2026)
  • Table 515. North America Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 516. North America Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 517. North America Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 518. North America Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 519. United States Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 520. United States Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 521. United States Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 522. United States Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 523. Canada Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 524. Canada Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 525. Canada Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 526. Canada Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 527. Mexico Antihypertensive Drugs Sales, by Disease Type K Units (2021-2026)
  • Table 528. Mexico Antihypertensive Drugs Sales, by End-users K Units (2021-2026)
  • Table 529. Mexico Antihypertensive Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 530. Mexico Antihypertensive Drugs Sales, by Therapeutic Class K Units (2021-2026)
  • Table 531. Research Programs/Design for This Report
  • Table 532. Key Data Information from Secondary Sources
  • Table 533. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antihypertensive Drugs: by Disease Type USD Million (2015-2020)
  • Figure 5. Global Antihypertensive Drugs: by End-users USD Million (2015-2020)
  • Figure 6. Global Antihypertensive Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 7. Global Antihypertensive Drugs: by Therapeutic Class USD Million (2015-2020)
  • Figure 8. South America Antihypertensive Drugs Share (%), by Country
  • Figure 9. Asia Pacific Antihypertensive Drugs Share (%), by Country
  • Figure 10. Europe Antihypertensive Drugs Share (%), by Country
  • Figure 11. MEA Antihypertensive Drugs Share (%), by Country
  • Figure 12. North America Antihypertensive Drugs Share (%), by Country
  • Figure 13. Global Antihypertensive Drugs: by Disease Type K Units (2015-2020)
  • Figure 14. Global Antihypertensive Drugs: by End-users K Units (2015-2020)
  • Figure 15. Global Antihypertensive Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 16. Global Antihypertensive Drugs: by Therapeutic Class K Units (2015-2020)
  • Figure 17. South America Antihypertensive Drugs Share (%), by Country
  • Figure 18. Asia Pacific Antihypertensive Drugs Share (%), by Country
  • Figure 19. Europe Antihypertensive Drugs Share (%), by Country
  • Figure 20. MEA Antihypertensive Drugs Share (%), by Country
  • Figure 21. North America Antihypertensive Drugs Share (%), by Country
  • Figure 22. Global Antihypertensive Drugs share by Players 2020 (%)
  • Figure 23. Global Antihypertensive Drugs share by Players (Top 3) 2020(%)
  • Figure 24. Global Antihypertensive Drugs share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 31. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 32. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 34. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Lupin Limited (India) Revenue: by Geography 2020
  • Figure 36. Ranbaxy Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 37. Ranbaxy Laboratories (India) Revenue: by Geography 2020
  • Figure 38. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 40. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 42. Daiichi Sankyo Company (Japan) Revenue, Net Income and Gross profit
  • Figure 43. Daiichi Sankyo Company (Japan) Revenue: by Geography 2020
  • Figure 44. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 45. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2020
  • Figure 46. Global Antihypertensive Drugs: by Disease Type USD Million (2021-2026)
  • Figure 47. Global Antihypertensive Drugs: by End-users USD Million (2021-2026)
  • Figure 48. Global Antihypertensive Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global Antihypertensive Drugs: by Therapeutic Class USD Million (2021-2026)
  • Figure 50. South America Antihypertensive Drugs Share (%), by Country
  • Figure 51. Asia Pacific Antihypertensive Drugs Share (%), by Country
  • Figure 52. Europe Antihypertensive Drugs Share (%), by Country
  • Figure 53. MEA Antihypertensive Drugs Share (%), by Country
  • Figure 54. North America Antihypertensive Drugs Share (%), by Country
  • Figure 55. Global Antihypertensive Drugs: by Disease Type K Units (2021-2026)
  • Figure 56. Global Antihypertensive Drugs: by End-users K Units (2021-2026)
  • Figure 57. Global Antihypertensive Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 58. Global Antihypertensive Drugs: by Therapeutic Class K Units (2021-2026)
  • Figure 59. South America Antihypertensive Drugs Share (%), by Country
  • Figure 60. Asia Pacific Antihypertensive Drugs Share (%), by Country
  • Figure 61. Europe Antihypertensive Drugs Share (%), by Country
  • Figure 62. MEA Antihypertensive Drugs Share (%), by Country
  • Figure 63. North America Antihypertensive Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Sanofi S.A (France)
  • Lupin Limited (India)
  • Ranbaxy Laboratories (India)
  • Merck & Co. (United States)
  • AstraZeneca plc (United Kingdom)
  • Daiichi Sankyo Company (Japan)
  • Takeda Pharmaceutical Company (Japan)
Additional players considered in the study are as follows:
Actelion (Switzerland) , United Therapeutics Corporation (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation